vs
KILROY REALTY CORP（KRC）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
KILROY REALTY CORP的季度营收约是REPLIGEN CORP的1.4倍（$272.2M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs 6.3%，领先0.4%），REPLIGEN CORP同比增速更快（13.6% vs -5.0%），KILROY REALTY CORP自由现金流更多（$450.3M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -1.2%）
基尔罗伊房地产公司是美国领先的房地产投资信托企业，主要在洛杉矶、旧金山、西雅图、圣地亚哥等美国西海岸核心市场开发、持有及运营优质办公、生命科学及混合用途物业，面向科技、生命科学、文创等领域租户，主打可持续的现代化办公空间。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
KRC vs RGEN — 直观对比
营收规模更大
KRC
是对方的1.4倍
$197.9M
营收增速更快
RGEN
高出18.6%
-5.0%
净利率更高
RGEN
高出0.4%
6.3%
自由现金流更多
KRC
多$432.7M
$17.6M
两年增速更快
RGEN
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $272.2M | $197.9M |
| 净利润 | $17.1M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | — | 9.0% |
| 净利率 | 6.3% | 6.7% |
| 营收同比 | -5.0% | 13.6% |
| 净利润同比 | -73.7% | 143.9% |
| 每股收益（稀释后） | $0.11 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KRCRGEN
| Q4 25 | $272.2M | $197.9M | ||
| Q3 25 | $279.7M | $188.8M | ||
| Q2 25 | $289.9M | $182.4M | ||
| Q1 25 | $270.8M | $169.2M | ||
| Q4 24 | $286.4M | $174.1M | ||
| Q3 24 | $289.9M | $154.9M | ||
| Q2 24 | $280.7M | $154.1M | ||
| Q1 24 | $278.6M | $151.3M |
净利润KRCRGEN
| Q4 25 | $17.1M | $13.3M | ||
| Q3 25 | $162.3M | $14.9M | ||
| Q2 25 | $79.6M | $14.9M | ||
| Q1 25 | $43.7M | $5.8M | ||
| Q4 24 | $65.0M | $-30.3M | ||
| Q3 24 | $57.7M | $-654.0K | ||
| Q2 24 | $54.5M | $3.3M | ||
| Q1 24 | $55.7M | $2.1M |
毛利率KRCRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率KRCRGEN
| Q4 25 | — | 9.0% | ||
| Q3 25 | — | 8.9% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | — | -5.1% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 1.3% |
净利率KRCRGEN
| Q4 25 | 6.3% | 6.7% | ||
| Q3 25 | 58.0% | 7.9% | ||
| Q2 25 | 27.4% | 8.2% | ||
| Q1 25 | 16.1% | 3.4% | ||
| Q4 24 | 22.7% | -17.4% | ||
| Q3 24 | 19.9% | -0.4% | ||
| Q2 24 | 19.4% | 2.2% | ||
| Q1 24 | 20.0% | 1.4% |
每股收益（稀释后）KRCRGEN
| Q4 25 | $0.11 | $0.24 | ||
| Q3 25 | $1.31 | $0.26 | ||
| Q2 25 | $0.57 | $0.26 | ||
| Q1 25 | $0.33 | $0.10 | ||
| Q4 24 | $0.50 | $-0.55 | ||
| Q3 24 | $0.44 | $-0.01 | ||
| Q2 24 | $0.41 | $0.06 | ||
| Q1 24 | $0.42 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $179.3M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $5.4B | $2.1B |
| 总资产 | $10.9B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资KRCRGEN
| Q4 25 | $179.3M | $767.6M | ||
| Q3 25 | $372.4M | $748.7M | ||
| Q2 25 | $193.1M | $708.9M | ||
| Q1 25 | $146.7M | $697.2M | ||
| Q4 24 | $165.7M | $757.4M | ||
| Q3 24 | $625.4M | $784.0M | ||
| Q2 24 | $835.9M | $809.1M | ||
| Q1 24 | $855.0M | $780.6M |
总债务KRCRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益KRCRGEN
| Q4 25 | $5.4B | $2.1B | ||
| Q3 25 | $5.5B | $2.1B | ||
| Q2 25 | $5.4B | $2.1B | ||
| Q1 25 | $5.4B | $2.0B | ||
| Q4 24 | $5.4B | $2.0B | ||
| Q3 24 | $5.4B | $2.0B | ||
| Q2 24 | $5.4B | $2.0B | ||
| Q1 24 | $5.4B | $2.0B |
总资产KRCRGEN
| Q4 25 | $10.9B | $2.9B | ||
| Q3 25 | $11.0B | $2.9B | ||
| Q2 25 | $10.9B | $2.9B | ||
| Q1 25 | $10.9B | $2.9B | ||
| Q4 24 | $10.9B | $2.8B | ||
| Q3 24 | $11.4B | $2.8B | ||
| Q2 24 | $11.5B | $2.9B | ||
| Q1 24 | $11.6B | $2.8B |
负债/权益比KRCRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $566.3M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $450.3M | $17.6M |
| 自由现金流率自由现金流/营收 | 165.4% | 8.9% |
| 资本支出强度资本支出/营收 | 42.6% | 4.1% |
| 现金转化率经营现金流/净利润 | 33.10× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $833.0M | $93.9M |
8季度趋势，按日历期对齐
经营现金流KRCRGEN
| Q4 25 | $566.3M | $25.7M | ||
| Q3 25 | $176.6M | $48.1M | ||
| Q2 25 | $143.7M | $28.6M | ||
| Q1 25 | $136.9M | $15.0M | ||
| Q4 24 | $541.1M | $39.2M | ||
| Q3 24 | $176.3M | $49.3M | ||
| Q2 24 | $88.7M | $42.2M | ||
| Q1 24 | $167.9M | $44.7M |
自由现金流KRCRGEN
| Q4 25 | $450.3M | $17.6M | ||
| Q3 25 | $148.7M | $43.4M | ||
| Q2 25 | $118.4M | $21.5M | ||
| Q1 25 | $115.6M | $11.4M | ||
| Q4 24 | $440.8M | $33.6M | ||
| Q3 24 | $147.2M | $42.3M | ||
| Q2 24 | $69.5M | $37.4M | ||
| Q1 24 | $151.9M | $36.4M |
自由现金流率KRCRGEN
| Q4 25 | 165.4% | 8.9% | ||
| Q3 25 | 53.1% | 23.0% | ||
| Q2 25 | 40.9% | 11.8% | ||
| Q1 25 | 42.7% | 6.8% | ||
| Q4 24 | 153.9% | 19.3% | ||
| Q3 24 | 50.8% | 27.3% | ||
| Q2 24 | 24.7% | 24.3% | ||
| Q1 24 | 54.5% | 24.0% |
资本支出强度KRCRGEN
| Q4 25 | 42.6% | 4.1% | ||
| Q3 25 | 10.0% | 2.5% | ||
| Q2 25 | 8.7% | 3.9% | ||
| Q1 25 | 7.9% | 2.1% | ||
| Q4 24 | 35.0% | 3.2% | ||
| Q3 24 | 10.1% | 4.5% | ||
| Q2 24 | 6.8% | 3.1% | ||
| Q1 24 | 5.7% | 5.5% |
现金转化率KRCRGEN
| Q4 25 | 33.10× | 1.93× | ||
| Q3 25 | 1.09× | 3.23× | ||
| Q2 25 | 1.81× | 1.92× | ||
| Q1 25 | 3.13× | 2.57× | ||
| Q4 24 | 8.32× | — | ||
| Q3 24 | 3.06× | — | ||
| Q2 24 | 1.63× | 12.70× | ||
| Q1 24 | 3.01× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
